Community protocol · Melanotan II
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: MT-2 · MT-II · MT-2 Melanotan 2 Acetate · Melanotin Receptor Type 2 · Synthetic melanocortin peptide
Sources checked: 27 August 2026
This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Quick context
Influences pigmentation and other melanocortin signals; safety and purity of unapproved products are uncertain.
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Amounts, timing and cycles
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Different amounts circulate online; no regulator-confirmed safe or effective dose exists.
Profile evidence level: anecdotal.
Community claims about time of day, fasting windows or training intervals are not validated clinical standards.
No individual recommendation.
Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community sourceReconstitution and U-100 conversion
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
Melanotan II is classified as “Non-selective melanocortin receptor agonist”. Influences pigmentation and other melanocortin signals; safety and purity of unapproved products are uncertain. This describes the investigated pathway but does not validate a community use, amount, route or combination.
This studies how a substance engages several melanocortin receptor subtypes at once rather than just one, potentially causing broader but less predictable effects, comparable to a master key rather than a single key. Various body responses are measured in parallel in studies.
This studies how activating melanocortin receptors affects pigmentation or sexual arousal signals, like a switch controlling different body functions depending on the receptor subtype. Skin pigmentation or physiological arousal markers are measured in studies.
This studies how skin pigment cells respond to signals that darken skin, potentially reducing sensitivity to sunlight, similar to how a photograph darkens with more exposure. Researchers typically measure skin pigment levels and light sensitivity in study participants.
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
Users compare tanning or skin changes after using melanocortin-related substances, often based on shared photos rather than medical examination. Such posts do not establish reviewed safety, especially for unapproved variants.
Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.
Vendors often advertise products with broad efficacy claims, comparison tables against competitors, and customer quotes. Such marketing statements are driven by sales interest and do not constitute independent scientific proof of efficacy.
Adverse effects and risk boundaries
Exclusion groups and professional assessment
Monitoring and laboratory markers
Evidence boundary
Safety and purity of unapproved products are uncertain, and robust human data are lacking.
Published evidence
Claims rely mostly on personal experience reports and vendor statements rather than controlled studies.
Melanotan II is a non-selective, unapproved precursor from which the approved agents afamelanotide and bremelanotide were developed.
Storage and stability
Troubleshooting and error sources
Regulatory status and WADA
No FDA- or EMA-approved medicinal product; efficacy and safety are not established.
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
Frequently asked questions
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
